Home > Boards > US OTC > Biotechs > Hepion Pharmaceuticals, Inc (HEPA)

What makes you think that?

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
TheAnnointedOne Member Profile
 
Followed By 85
Posts 6,070
Boards Moderated 0
Alias Born 04/08/17
160x600 placeholder
Hepion Pharmaceuticals gets FDA fast track designation for CRV431 to treat liver disease Seeking Alpha - 11/30/2021 8:56:16 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/30/2021 8:10:45 AM
Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH GlobeNewswire Inc. - 11/30/2021 8:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 11/26/2021 6:09:13 AM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 11/19/2021 5:01:33 PM
Hepion Pharma reports anti-cancer activity of CRV431 in a liver cancer study in mice Seeking Alpha - 11/16/2021 9:11:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/16/2021 8:54:15 AM
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study GlobeNewswire Inc. - 11/16/2021 8:45:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/15/2021 4:50:28 PM
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021 GlobeNewswire Inc. - 11/10/2021 8:00:00 AM
Anti-Cancer Mechanism of Hepion Pharmaceuticals’ CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021 GlobeNewswire Inc. - 11/10/2021 7:55:00 AM
Hepion Pharmaceuticals Presents at the EquitiesIQ Q4 2021 Investor Forum GlobeNewswire Inc. - 11/4/2021 8:00:00 AM
Hepion Pharmaceuticals to Present at the EquitiesIQ Q4 2021 Investor Forum GlobeNewswire Inc. - 11/2/2021 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/8/2021 4:31:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/7/2021 4:25:14 PM
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference GlobeNewswire Inc. - 10/7/2021 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/30/2021 5:23:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/29/2021 9:23:16 AM
All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431 GlobeNewswire Inc. - 9/29/2021 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2021 8:29:53 AM
Additional Data from Hepion Pharmaceuticals’ Phase 2a ‘AMBITION’ Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ‘ASCEND-NASH’ Clinical Program GlobeNewswire Inc. - 9/13/2021 8:00:00 AM
Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a ‘AMBITION’ Clinical Trial of CRV431 in NASH GlobeNewswire Inc. - 9/10/2021 4:05:00 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 9/7/2021 6:00:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/23/2021 9:20:13 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 8/23/2021 6:09:24 AM
TheAnnointedOne   Friday, 06/21/19 11:45:46 AM
Re: Roadtojourney post# 849
Post # of 1905 
What makes you think that?

Buy the green, sell the green.



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences